Disclosed is a pharmaceutical emulsion formulation comprising: (a) clevidipine, or a pharmaceutically acceptable salt or ester thereof, present at about 0.01 to about 1.0% w/v； (b) an antimicrobial agent, EDTA, present at about 0.001 to about 1.5% w/v； (c) a lipid preferably present at about 2 to about 30% w/v； (d) an emulsifier, preferably present at about 0.2 to about 2.0% w/v； (e) a tonicity modifier, preferably present at about 2 to about 3% w/v； and (f) water. In a preferred pharmaceutical formulation comprises: (a) clevidipine butyrate, present at about 0.01 to about 1% w/v； (b) EDTA, present at about 0.001 to about 0.1% w/v； (c) soybean oil, present at about 4 to about 30% w/v； (d) purified egg yolk phospholipids, present at about 0.2 to about 2% w/v； (e) glycerin, present at about 2 to about 3% w/v； and (f) water up to 100%.
